Literature DB >> 18288585

Community pharmacists' attitudes towards medicines use reviews and factors affecting the numbers performed.

Asam Latif1, Helen Boardman.   

Abstract

OBJECTIVE OF THE STUDY: Medicines use review and prescription intervention ('MUR services') is the first advanced service within the NHS community pharmacy contract and is a structured review that is undertaken by a pharmacists with patients on multiple medicines. The objective of this study was to investigate factors that influence the number of Medicines use reviews (MURs) performed by community pharmacists and to explore community pharmacists' attitudes towards the service. Setting This study was conducted with pharmacists who were employed by one UK community pharmacy chain.
METHOD: A questionnaire was developed to investigate factors that influence the number of MURs performed and pharmacists' attitudes towards MURs. It consisted of a series of attitudinal statements together with brief demographic data. Questionnaires were distributed to a sample of 280 pharmacists accredited to provide the service during April and May 2006. MAIN OUTCOME MEASURE: Factors affecting the number of MURs performed and community pharmacists' attitudes towards MURs.
RESULTS: Sixty per cent (167/280) of pharmacists returned a completed questionnaire. Twenty-seven per cent of respondents had not performed any MURs, 43% had conducted one to 14 reviews and 31% had conducted 15 or more. Job title affected the number of reviews performed; respondents categorised as 'Store based' pharmacists performed significantly more MURs than those working as 'Locums' but not significantly more than 'Managing' pharmacists. Pharmacists reporting access to an accredited consultation area performed significantly more MURs than those who did not. Those working more than 20 h per week performed significantly more MURs than those working less. Gender, time since qualification, the pharmacy size and those having or currently undertaking a clinical diploma were not found to be associated with the number of MURs performed. Most respondents reported that MURs were an opportunity for pharmacist to use their professional skills in an extended role and patients would benefit from the service. However they reported concerns about GPs opinion of the service, lack of time and support staff to conduct MURs and were unhappy about consultation areas.
CONCLUSION: This study demonstrates that pharmacists perceive MURs to be an opportunity for an extended role and of value to patients. However, this study has identified perceived barriers, including the availability of a consultation area suitable for performing MURs, time to perform MURs and support staff. The number of MURs performed by pharmacists appears to be affected by the pharmacists' job title, their working hours and the presence of a consultation area. Additional support for 'locum' pharmacists was also highlighted and may be needed.

Entities:  

Mesh:

Year:  2008        PMID: 18288585     DOI: 10.1007/s11096-008-9203-x

Source DB:  PubMed          Journal:  Pharm World Sci        ISSN: 0928-1231


  3 in total

1.  Perceptions around concordance--focus groups and semi-structured interviews conducted with consumers, pharmacists and general practitioners.

Authors:  Jasmina Bajramovic; Lynne Emmerton; Susan E Tett
Journal:  Health Expect       Date:  2004-09       Impact factor: 3.377

2.  Patient non-compliance: deviance or reasoned decision-making?

Authors:  J L Donovan; D R Blake
Journal:  Soc Sci Med       Date:  1992-03       Impact factor: 4.634

Review 3.  Home medicines review. The how and why for GPs.

Authors:  Graham Emblen; Emmett Miller
Journal:  Aust Fam Physician       Date:  2004 Jan-Feb
  3 in total
  18 in total

1.  Community pharmacists' perceptions of medicines use reviews and quality assurance by peer review.

Authors:  Geoffrey Harding; Michael Wilcock
Journal:  Pharm World Sci       Date:  2010-03-28

2.  The influence of pharmacy and pharmacist characteristics on the secondary prevention of cardiovascular disease.

Authors:  Hanni Prihhastuti Puspitasari; Parisa Aslani; Ines Krass
Journal:  Int J Clin Pharm       Date:  2015-05-12

3.  Drug related problems after discharge from an Australian teaching hospital.

Authors:  Glena R Ellitt; Ellinor Engblom; Parisa Aslani; Tommy Westerlund; Timothy F Chen
Journal:  Pharm World Sci       Date:  2010-06-26

4.  Community pharmacies automation: any impact on counselling duration and job satisfaction?

Authors:  Afonso Miguel Cavaco; Anette Aaland Krookas
Journal:  Int J Clin Pharm       Date:  2013-11-20

5.  Medication use review in Qatar: are community pharmacists prepared for the extended professional role?

Authors:  Ahmed Hussein Babiker; Louise Carson; Ahmed Awaisu
Journal:  Int J Clin Pharm       Date:  2014-10-08

6.  Community pharmacists' perspectives on implementation of Medicines Use Review in Slovenia.

Authors:  Urska Nabergoj Makovec; Mitja Kos; Nina Pisk
Journal:  Int J Clin Pharm       Date:  2018-06-16

7.  What proportion of prescription items dispensed in community pharmacies are eligible for the New Medicine Service?

Authors:  Katharine M Wells; Matthew J Boyd; Tracey Thornley; Helen F Boardman
Journal:  BMC Health Serv Res       Date:  2014-03-07       Impact factor: 2.655

8.  Medication adherence and community pharmacy: a review of education, policy and research in England.

Authors:  Sarah Clifford; Sara Garfield; Lina Eliasson; Nick Barber
Journal:  Pharm Pract (Granada)       Date:  2010-03-15

9.  Positioning pharmacists' roles in primary health care: a discourse analysis of the compensation plan in Alberta, Canada.

Authors:  Christine A Hughes; Rene R Breault; Deborah Hicks; Theresa J Schindel
Journal:  BMC Health Serv Res       Date:  2017-11-23       Impact factor: 2.655

10.  Comparison of pharmacist and public views and experiences of community pharmacy medicines-related services in England.

Authors:  Ruth M Rodgers; Shivaun M Gammie; Ruey Leng Loo; Sarah A Corlett; Janet Krska
Journal:  Patient Prefer Adherence       Date:  2016-09-09       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.